@the.biotech.breakdown: The FDA approved Hibsago (bepirovirsen), a new treatment that could help some people with chronic hepatitis B achieve a functional cure — potentially allowing them to stop long term treatment. Unlike traditional antivirals, this drug targets viral RNA to help reduce hepatitis B proteins in the body. But there’s a catch: it doesn’t work for everyone, and a functional cure doesn’t necessarily mean the virus is completely eliminated. One breakthrough at a time. Follow along for the next Biotech Breakdown! ##fdaapproved##pharma##hepatitisb##thebiotechbreakdown##biotechnology

The Biotech Breakdown

Open In TikTok:

Region: US

Friday 23 October 2026 01:55:47 GMT